| # | Drug | Count |
|---|---|---|
| 0 | ALEMTUZUMAB | 23 |
| 1 | NIVOLUMAB | 18 |
| 2 | PEMBROLIZUMAB | 9 |
| 3 | IPILIMUMAB | 7 |
| 4 | OMEPRAZOLE MAGNESIUM | 7 |
| 5 | OMEPRAZOLE | 6 |
| 6 | ATEZOLIZUMAB | 5 |
| 7 | ACETAMINOPHEN | 4 |
| 8 | ACETAMINOPHEN 500MG | 4 |
| 9 | ACETAMINOPHEN TABLET EXTENDED RELEASE | 4 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | SULFACETAMIDE SODIUM | 1 | 0.0020 |
| 1 | DOSTARLIMAB | 3 | 0.0012 |
| 2 | ALEMTUZUMAB | 23 | 0.0012 |
| 3 | MOGAMULIZUMAB-KPKC | 1 | 0.0007 |
| 4 | DROPERIDOL | 1 | 0.0006 |
| 5 | MITOTANE | 1 | 0.0005 |
| 6 | ROPEGINTERFERON ALFA-2B | 1 | 0.0005 |
| 7 | CLADRIBINE | 4 | 0.0004 |
| 8 | NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE | 1 | 0.0004 |
| 9 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 1 | 0.0003 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | CD52-directed Cytolytic Antibody [EPC] | 23 | 0.0012 |
| 1 | Chemokine Receptor Type 4 Interaction [EPC] | 1 | 0.0007 |
| 2 | Interferon alfa-2b [EPC] | 1 | 0.0005 |
| 3 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 33 | 0.0003 |
| 4 | CTLA-4-directed Blocking Antibody [EPC] | 7 | 0.0001 |
| 5 | Dopamine-2 Receptor Antagonist [EPC] | 1 | 0.0001 |
| 6 | Cephalosporin Antibacterial [EPC] | 1 | 0.0001 |
| 7 | Sphingosine 1-phosphate Receptor Modulator [EPC] | 1 | 0.0001 |
| 8 | Influenza A M2 Protein Inhibitor [EPC] | 1 | 0.0001 |
| 9 | Sympathomimetic-like Agent [EPC] | 2 | 0.0001 |